Log in to your Inderes Free account to see all free content on this page.

Dicot Pharma

0.35 SEK

+0.57 %

Less than 1K followers

DICOT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+0.57 %

-22.11 %

-58.11 %

-36.79 %

+45.98 %

+62.01 %

+6.83 %

-34.69 %

-86.15 %

Dicot Pharma is developing the drug candidate LIB-01, which is expected to be a potency drug for the treatment of erectile dysfunction and premature ejaculation. Duration of action and fewer side effects are the main desired properties. Dicot's main strategy is to continuously evaluate industrial partnerships during the development of LIB-01 to take the drug candidate to commercialization.

Market cap

711.31M SEK

Turnover

2.77M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

18.2.

2026

Annual report '25

30.4.

2026

Interim report Q1'26

6.5.

2026

General meeting '26

All

Press releases

ShowingAll content types

Regulatory press release11/21/2025, 9:45 AM

Dicot Pharma submits new patent application for LIB-01 based on positive phase 2a results showing long-term effect

Press release11/13/2025, 12:45 PM

Dicot Pharma presents at Stora Aktiedagarna on November 26

Regulatory press release10/30/2025, 8:10 AM

Nomination Committee appointed for Dicot Pharma AB

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release10/23/2025, 2:00 PM

Dicot Pharma presents interim report Q3 2025 and invites to a live broadcast

Regulatory press release10/23/2025, 5:15 AM

Dicot Pharma Announces Positive Results from its Phase 2a Study

Press release9/25/2025, 6:00 AM

Dicot Pharma to present at Oppenheimer Life Sciences Company Showcase

Press release8/27/2025, 5:00 AM

Dicot Pharma included in global stock index

Regulatory press release8/20/2025, 9:57 AM

Dicot Pharma’s Phase 2a study completed – results within three months

Regulatory press release8/12/2025, 6:15 AM

Dicot Pharma presents interim report Q2 2025

Regulatory press release6/25/2025, 12:40 PM

Dicot Pharma AB: All participants in Dicot Pharma's phase 2a study are dosed

Regulatory press release5/28/2025, 6:40 AM

Dicot Pharma AB: Dicot Pharma's new findings on mechanism of action: "affects the nerves controlling penile erection"

Regulatory press release5/6/2025, 4:54 PM

Dicot Pharma AB: Report from the Annual General Meeting of Dicot Pharma

Regulatory press release4/29/2025, 6:15 AM

Dicot Pharma AB: Dicot Pharma presents interim report Q1 2025

Regulatory press release4/3/2025, 7:00 AM

Dicot Pharma AB: Summon to Annual General Meeting in Dicot Pharma May 6 at 17.00

Regulatory press release4/2/2025, 6:30 AM

Dicot Pharma AB: Dicot Pharma's TO 6 subscribed at 96% and provides the company SEK 43.8 million

Regulatory press release3/26/2025, 12:43 PM

Dicot Pharma AB: Last day of trading in Dicot Pharma TO 6 warrants tomorrow, March 27

Press release3/17/2025, 2:34 PM

Dicot Pharma AB: Dicot Pharma invites to a Q&A session on TO 6

Regulatory press release3/17/2025, 7:15 AM

Dicot Pharma AB: Exercise Period for Warrants TO6 in Dicot Pharma Begins Today

Regulatory press release3/13/2025, 10:50 AM

Dicot Pharma AB: Letters of Intent from Major Shareholders, Board, and Management to Subscribe for SEK 11 million in Dicot Pharma's TO 6, Running Until March 31, 2025

Regulatory press release3/11/2025, 7:30 AM

Dicot Pharma AB: Subscription Price SEK 0.38 for Warrants TO 6 in Dicot Pharma Determined; corresponding to SEK 0.19 per share

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.